Acquisition Details#
BioMarin Pharmaceutical Inc. has finalized its acquisition of Amicus Therapeutics for $14.50 per share, totaling approximately $4.8 billion. This all-cash transaction significantly boosts BioMarin's presence in the market, where it currently has a market capitalization of $10.2 billion.
Expanded Treatment Portfolio#
With this acquisition, BioMarin adds two key treatments to its offerings for lysosomal storage diseases. The first is Galafold (migalastat), an oral medication for Fabry disease, approved in over 40 countries, including the U.S., EU, U.K., and Japan. Galafold acts as a pharmacological chaperone, helping patients with specific genetic variants of the disease. The second treatment is a combination therapy, Pombiliti (cipaglucosidase alfa-atga) plus Opfolda (miglustat), designed for adult patients with late-onset Pompe disease who are not seeing improvements with their current enzyme replacement therapy.
Financial Health and Future Outlook#
BioMarin has shown solid financial performance, being profitable over the last year with nearly 13% revenue growth. The company holds more cash than debt, indicating a strong balance sheet. BioMarin plans to provide updated financial guidance for the fiscal year 2026 during its earnings call on May 4, 2026.
Strategic Goals#
Alexander Hardy, BioMarin's President and CEO, stated that this acquisition aligns with the company’s strategy to diversify and strengthen its growth profile while focusing on delivering medicines for rare diseases. The acquisition also marks a significant step as Amicus will become a wholly owned subsidiary of BioMarin, further solidifying its position in the rare disease market.